Cantor’s Mara Goldstein may be playing it cautious on Celgene, but she still spotlights 8% upside potential for this biotech player.
Celgene Corporation (NASDAQ:CELG) and the Lymphoma Study Association (LYSA) gave investors reason to raise a red flag today, as shares start to slip …
Celgene Corporation (NASDAQ:CELG) announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective …
Cantor: CELG pipeline needs commercial juice; Cowen: Sarepta soars on strong Exondys 51 orphan launch.
Eric Schmidt worries CELG investors will further question franchises’ longevity in the 3Q earnings aftermath.
Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.
Celgene Corporation (NASDAQ:CELG) announced that the FDA has placed a partial clinical hold on five trials and a full clinical hold on one …
Gilead Sciences, Inc. Cowen analyst Phil Nadeau is out with a research note on shares of Gilead Sciences, Inc.
Insider transactions can be the foundation of numerous trading strategies and signals. For example, we found that a strategy based on only top-ranked …
Celgene Corporation (NASDAQ:CELG) announced results from the phase 2a SLE-001 trial evaluating CC-220, the Company’s investigational, oral immunomodulatory compound, at the Annual European …
